Exploring APOBECs as therapeutic vulnerabilities in Multiple Myeloma

Basic Information

Funding Cycle : 2021-2022
Name : Florian Kuchenbauer
Type of Award : Translational Research Award
Home Institution : Terry Fox Laboratory, BC Cancer Research Institute, Canada


The project aims to explore APOBECs as potential therapeutic targets in multiple myeloma (MM). Aim 1 focuses on identifying druggable APOBEC targets by modulating their expression in MM cells and assessing their impact on cellular characteristics. This involves genetic manipulations and functional assays to determine downstream pathways affected by APOBEC activation. Aim 2 investigates the role of APOBEC3s in drug resistance and relapse of MM patients by inducing APOBEC expression and testing drug responses in cell lines and patient samples. RNA-Seq, WGS, and proteomics analyses will elucidate the mechanisms underlying drug resistance. The project aims to identify therapeutic opportunities for high-risk and relapsed MM patients, potentially leading to early clinical trials.

Why Become a Member

The International Myeloma Society is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. The purpose of this society is to promote research, education, clinical studies (including diagnosis and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide.

The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.

Stay updated on our Events